Inspire Medical Systems, Inc.

As of June 30, 2026, Inspire Medical Systems, Inc. carries a market capitalization of 1.29B, placing it among publicly traded companies globally. Its enterprise value stands at 997.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Inspire Medical Systems, Inc.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Inspire Medical Systems, Inc. has 28.91M shares outstanding.

As of June 30, 2026, Inspire Medical Systems, Inc. trades at a trailing price-to-earnings ratio of 9.56. The price-to-sales ratio is 1.44, and the price-to-book ratio stands at 1.56.

As of June 30, 2026, Inspire Medical Systems, Inc. trades at an EV/EBITDA multiple of 13.99 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 997.96M versus a market cap of 1.29B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Inspire Medical Systems, Inc. maintains a current ratio of 8.55, meaning it holds 8.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.52, indicating elevated leverage, while an interest coverage ratio of 536.31 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Inspire Medical Systems, Inc. posted a return on equity (ROE) of 17.96, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 15.63, measuring how efficiently the asset base is converted into earnings. The company generates approximately 685,408.58 in revenue per employee across its workforce of 1,311.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.85 indicates how many times Inspire Medical Systems, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Inspire Medical Systems, Inc. recorded an income tax benefit of -65.66M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 69.38M, leaving 135.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Inspire Medical Systems, Inc.'s stock has declined approximately 10.94% over the past 52 weeks. The 50-day moving average sits at 67.18, while the 200-day moving average is 59.33.

Over the twelve months ended June 30, 2026, Inspire Medical Systems, Inc. generated 898.74M in revenue and converted that into 135.04M in net income, yielding earnings per share of 4.64. EBITDA reached 71.33M, while operating income came in at 54.12M.

As of June 30, 2026, Inspire Medical Systems, Inc. holds 320.68M in cash and equivalents against 29.09M in total debt, resulting in a net debt position of -127.76M. Total book value stands at 825.58M, with working capital of 537.49M providing operational flexibility.

Inspire Medical Systems, Inc. produced 157.07M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -21.09M in capital expenditures, free cash flow totaled 135.98M - equivalent to 4.70 per share.

Over the twelve months ended June 30, 2026, Inspire Medical Systems, Inc. posted a gross margin of 86.13, reflecting its pricing power and cost economics. The operating margin of 6.02 and net profit margin of 15.03 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 10.47, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Inspire Medical Systems, Inc. shareholders.

As of June 30, 2026, Inspire Medical Systems, Inc. has an Altman Z-Score of 9.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.